5-methoxy-,-dimethyltrytpamine (5-MeO-DMT) analogs are used as recreational drugs, but they are also being developed as potential medicines, warranting further investigation into their pharmacology. Here, we investigated the neuropharmacology of 5-MeO-DMT and several of its -alkyl, -allyl, and 2-methyl analogs, with three major aims: 1) to determine in vitro receptor profiles for the compounds, 2) to characterize in vitro functional activities at serotonin (5-HT) 2A receptors (5-HT) and 1A receptors (5-HT), and 3) to examine the influence of 5-HT on 5-HT-mediated psychedelic-like effects in the mouse head twitch response (HTR) model. In vitro receptor binding and functional assays showed that all 5-MeO-DMT analogs bind with high affinity and activate multiple targets (e.g., 5-HT receptor subtypes, alpha adrenergic receptors), including potent effects at 5-HT and 5-HT. In C57Bl/6J mice, subcutaneous injection of the analogs induced HTRs with varying potencies (ED range = 0.2-1.8 mg/kg) and maximal effects ( range = 20-60 HTRs/30 min), while inducing hypothermia and hypolocomotion at higher doses (ED range = 3.2-20.6 mg/kg). 5-HT antagonist pretreatment blocked drug-induced HTRs, whereas 5-HT antagonist pretreatment enhanced HTRs. In general, ,-dialkyl and -isopropyl derivatives displayed HTR activity, while the -methyl, -ethyl, and 2-methyl analogs did not. Importantly, blockade of 5-HT unmasked latent HTR activity for the -ethyl analog and markedly increased maximal responses for other HTR-active compounds (40-90 HTRs/30 min), supporting the notion that 5-HT agonist activity can dampen 5-HT-mediated HTRs. Suppression of 5-HT-mediated HTRs by 5-HT only occurred after high 5-MeO-DMT doses, suggesting involvement of other receptors in modulating psychedelic-like effects. Overall, our findings provide key information about the receptor target profiles for 5-MeO-DMT analogs, the structure-activity relationships for inducing psychedelic-like effects, and the critical role of 5-HT agonism in modulating acute psychoactive effects of 5-HT agonists.

Download full-text PDF

Source
http://dx.doi.org/10.1021/acschemneuro.4c00513DOI Listing

Publication Analysis

Top Keywords

5-ht
14
5-meo-dmt analogs
12
psychedelic-like effects
12
2-methyl analogs
8
vitro receptor
8
5-ht receptors
8
receptors 5-ht
8
effects 5-ht
8
htrs/30 min
8
5-ht antagonist
8

Similar Publications

Background: Neuroleptic malignant syndrome (NMS) is a psychiatric-neurologic emergency that may require intensive care management. There is a paucity of information about NMS as a critical illness. We reviewed the Mayo Clinic experience.

View Article and Find Full Text PDF

Response to: Letter regarding 'Management of serotonin syndrome (toxicity)'.

Br J Clin Pharmacol

January 2025

Clinical Toxicology Research Group, NewMed II, Level 5, University of Newcastle, Newcastle, New South Wales, Australia.

View Article and Find Full Text PDF

Objective: Tapentadol causes fewer gastrointestinal adverse events than other potent opioid analgesics because of its low affinity for opioid receptors; however, development of symptoms related to central nervous system disorders, including delirium, has not been well-studied. This study aimed to identify the factors that influence the development of delirium after initiation of tapentadol therapy in hospitalized patients with cancer.

Design: Retrospective study.

View Article and Find Full Text PDF

Parkinson's disease arises from the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to motor symptoms such as akinesia, rigidity, and tremor at rest. The non-motor component of Parkinson's disease includes increased neuropathic pain, the prevalence of which is 4 to 5 times higher than the general rate. By studying a mouse model of Parkinson's disease induced by 6-hydroxydopamine, we assessed the impact of dopamine depletion on pain modulation.

View Article and Find Full Text PDF

Clozapine is a potent serotonin receptor antagonist and commonly used for the treatment of Schizophrenia. The study aimed to develop and optimize the transdermal matrix patch of clozapine. A 3-level, 3-factor Central Composite Design was applied to examine and validate the impact of various formulation variables, Eudragit, PEG, and oleic acid on in vitro drug release, flux, and tensile strength (TS).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!